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The  endocannabinoid  anandamide  (AEA)  causes  vasorelaxation  in  animal  studies.  Although  circulating
AEA  levels  are  increased  in  many  pathologies,  little is known  about  its  vascular  effects  in humans.  The
aim  of this  work  was  to  characterise  the effects  of  AEA  in  human  arteries.  Ethical  approval  was  granted
to  obtain  mesenteric  arteries  from  patients  (n  = 31) undergoing  bowel  resection.  Wire  myography  was
used  to probe  the  effects  and  mechanisms  of action  of  AEA.  RT-PCR  was  used  to  conﬁrm  the  presence
of  receptor  mRNA  in human  aortic  endothelial  cells  (HAECs)  and  intracellular  signalling  proteins  were
measured  using  multiplex  technology.  AEA  caused  vasorelaxation  of  precontracted  human  mesenteric
arteries  with  an  Rmax of  ∼30%.  A synthetic  CB1 agonist  (CP55940)  caused  greater  vasorelaxation  (Rmax
∼60%)  while  a CB2 receptor  agonist  (HU308)  had  no effect  on vascular  tone.  AEA-induced  vasorelaxation
was  inhibited  by  removing  the  endothelium,  inhibition  of  nitric  oxide  (NO)  synthase,  antagonising  the
CB1 receptor  and  antagonising  the  proposed  novel  endothelial  cannabinoid  receptor  (CBe). AEA-induced
vasorelaxation  was  not  affected  by CB2 antagonism,  by  depleting  sensory  neurotransmitters,  or  inhibiting
cyclooxygenase  activity.  RT-PCR  showed  CB1 but  not  CB2 receptors  were  present  in  HAECs,  and  AEAaracetamol
and  CP55940  had  similar  proﬁles  in  HAECs  (increased  phosphorylation  of JNK,  NFB,  ERK,  Akt,  p70s6K,
STAT3  and  STAT5).  Post  hoc  analysis  of  the  data set showed  that  overweight  patients  and  those  taking
paracetamol  had  reduced  vasorelaxant  responses  to  AEA.  These  data  show  that  AEA causes  moderate
endothelium-dependent,  NO-dependent  vasorelaxation  in  human  mesenteric  arteries  via activation  of
CB1 receptors.
© 2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
The ﬁrst discovered endogenous cannabinoid agonist, anan-
amide (AEA) was shown to induce vasorelaxation of rabbit
erebral arterioles in the early nineties [1]. Since then, AEA is one
f the most widely studied cannabinoids in the vasculature [2].
nimal studies have shown that the acute vasorelaxant response
o AEA is underpinned by several pathways including cannabi-
oid (CB1, CB2 and CBe (proposed cannabinoid receptor located
n the endothelium)) receptor activation, activation of transient
eceptor potential (TRP) channels, with subsequent endothelium
erived hyperpolarising factor (EDHF) and/or nitric oxide (NO)
ediated relaxation of vascular smooth muscle [3–5]. The original
ork of Ellis and colleagues [1] also found that AEA causes vasore-
axation through its metabolism to other vasodilator substances.
owever, in the rat mesentery, metabolism of AEA appears to limit
∗ Corresponding author.
E-mail address: saoirse.osullivan@nottingham.ac.uk (S.E. O’Sullivan).
ttp://dx.doi.org/10.1016/j.phrs.2016.08.028
043-6618/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
its vasorelaxant effects [6]. A slowly developing (over 2 h) vasore-
laxant response to AEA has also been observed in rat aortae [7],
which is inhibited by a peroxisome proliferator-activated recep-
tor gamma  (PPAR)  antagonist, endothelium removal, NO synthase
and superoxide dismutase inhibition.
Despite the wealth of studies showing that AEA causes acute
vasorelaxation of mesenteric arteries in several animal species,
the effects of AEA are unknown in human mesenteric arteries.
Indeed, investigations into the direct effects of AEA in human
vasculature are limited and conﬂicting. AEA is ineffective as a
vasorelaxant in myometrial arteries [8]. However, topical applica-
tion of AEA causes increased blood ﬂow in the forearm circulation
via TRPV1 activation [9]. AEA also causes maximal vasorelax-
ation of human pulmonary arteries through its metabolism to
vasoactive prostanoids and activation of CBe [10]. Interestingly, we
recently showed that the mechanisms of action of another endo-
cannabinoid, 2-arachidonoylglycerol (2-AG), is different in human
mesenteric arteries compared to that previously observed in ani-
mal  mesenteric arteries, suggesting further research is required
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Patient characteristics.
Characteristic Range Mean ± SEM
Ethnicity 27 UK white
Male 21
Female 6
Age 32–82 66 ± 2
Weight (kg) 49–122 81 ± 4
BMI  (kg/m2) 17.6–36.7 27.4 ± 1
Smoking habits
Non smokers 21
0–10 CPD 3
10–20 CPD 3
Drinking habits
<10 units p/w 17
10–20 units p/w 8
>20 units p/w 2
Operation
Right Hemicolectomy 7
Left Hemicolectomy 2
Sigmoid Colectomy 7
Anterior Resection 6
Abdominoperineal Resection 1
Total colectomy 4
Reason for surgery
Cancer 16
Inﬂammatory bowel disorder 11
Dukes Staging
Dukes A 8
Dukes B 4
Dukes C 3
Dukes D 1
Systolic Blood Pressure (mm/Hg) 110–172 142 ± 3
Diastolic Blood Pressure (mm/Hg) 65 ± 101 84 ± 2
Diabetic 7
Heart Disease 22
Heart Failure 0
Hypercholesterolemia 13
Hypertensive 15
-1 adrenoceptor antagonist (total) 1
Alfuzosin 0
terazocin 1
ACE Inhibitors (total) 7
Lisinopril 5
Ramipril 2
AT1 receptor antagonists (total) 2
Losartan 1
Irbesartan 1
Beta Blockers (total) 5
Metoprolol 1
Atenolol 3
Propranolol 1
Calcium channel blocker (total) 2
Amlodipine 1
Nifedipine 1
Lodipine 0
Digoxin 1
Diuretics (total) 2
Furosemide 2
GTN 3
Hypoglycaemic Medication (total) 5
Gliclazide 5
Metformin 4
Analgesia Medication (total) 12
Aspirin 4
Ibuprofen 1
Paracetamol 6
CoCodamol 3
Tramadol 2
Statin (total) 14
Atorvastatin 4
Simvastatin 9
Pravastatin 1
Thiazolidinedione (total) 1C.P. Stanley et al. / Pharmacolo
o understand the role and effects of endocannabinoids in human
asculature [11].
Plasma AEA concentrations are reported to be between
.3–2.5 nmol/L [12], but are raised in patients suffering from dis-
ases that affect the cardiovascular system, for example, in obese
atients [13], type-2 diabetics [14], patients with coronary dys-
unction [15] and in patients with portal hypertension associated
ith cirrhosis [16]. Animal studies have shown that increased
EA levels are associated with decreased arterial contractions
nd enhanced vasorelaxant responses in the mesenteric arteries
f biliary cirrhotic rats [17]. Domencali and colleagues [18] also
howed that the vasorelaxant response to AEA was enhanced in cir-
hotic rats, associated with an increase in CB1 and TPRV1 receptor
xpression. However, in obese rats, anandamide-induced relax-
tion is decreased in resistance arteries, associated with decreased
annabinoid receptor expression and increased anandamide degra-
ation [19]. We  have shown that the responses to AEA are reduced
n the Zucker diabetic model, which appears to be brought about
y enhanced metabolism of these endocannabinoids, including the
roduction of vasoconstrictor metabolites acting at the thrombox-
ne receptor (Wheal et al., under review). Looking at the effects of
atient characteristics on vasorelaxant responses to 2-AG, we found
hat 2-AG responses were reduced in those with heart disease and
ype 2 diabetes, and in those taking NSAIDS, statins or anti-diabetic
edication [11].
In light of this background, we hypothesised that anandamide
ould cause acute vasorelaxation of human mesenteric arteries
nd that these responses would be affected by medical conditions.
o address this hypothesis, the aims of the study were to assess
he potential vasorelaxant effect of AEA in isolated human mesen-
eric arteries, to investigate the mechanisms of how this might be
rought about, and to establish any potential effect of disease state
n AEA responses.
. Methods
.1. Chemicals
All salts, L-NAME, indomethacin and bradykinin were supplied
y Sigma Chemical Co. (Poole, UK). AEA, AM251, AM630, and
apsaicin were purchased from Tocris (Bristol, UK). L-NAME and
ndomethacin were dissolved in PSS solution. AEA, bradykinin and
apsaicin were all dissolved in ethanol at 10 mmol/L with further
ilutions made in distilled water. AM251, O-1918 and AM630 were
issolved in DMSO at 10 mmol/L with further dilutions made in
istilled water.
Ethical approval was  granted by the Derbyshire Research Ethics
ommittee and Derbyshire Hospitals Trust Research and Devel-
pment to take mesenteric tissue from 31 patients undergoing
urgical treatment of bowel carcinoma and inﬂammatory bowel
isorders. Patient characteristics for those who  gave access to
edical notes are presented in Table 1. Informed written consent
as taken according to the Declaration of Helsinki. Mesenteric
issue containing small mesenteric arteries (700 ± 49 m diame-
er (mean ± s.e.m)) were collected, dissected free of all connective
issue and perivascular fat, mounted on to a Mulvany Halpern myo-
raph and normalised to 90% of 13.3 kPa in physiological saline
olution (PSS) as previously described [11,20]. The endothelial
esponse to a single concentration of bradykinin (10 mol/L) was
ested to ensure endothelial integrity, and only vessels showing
70% relaxation were used (mean response was 84 ± 1.6%). After
ashout, arteries were contracted with a combination of U46619
nd endothelin-1. The average level of contraction of all arteries
as 17 ± 1 mN  (representing 89 ± 4% of the maximal response to a
igh potassium solution in these arteries). When a stable tone was
Pioglitazone 1
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Fig. 1. CB1 but not CB2 agonists cause vasorelaxation of human mesenteric arteries. A representative trace showing a concentration response curve to anandamide (AEA)
(A).  Graphical representation of concentration-response curves to acute (B, n = 12 patients) and time-dependent (D, n = 5 patients) exposure to anandamide. Concentration-
response curves to anandamide in uncontracted arteries (C, n = 7 patients). Concentration responses to the CB1 receptor agonist CP55940 (E, n = 12 patients) or the CB2 agonist
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rror  bars showing SEM. Comparisons between intervention (cannabinoid) and co
easures ANOVA with Sidak’s multiple comparison at each concentration. * P < 0.05
chieved, cumulative concentration-response curves were con-
tructed to AEA. In acute studies, AEA was added in 5 min  intervals,
ith measurements taken in the ﬁnal minute of each concentration
ddition and expressed as percentage relaxation of pre-imposed
one. Vasorelaxant responses were compared to ethanol-treated
ehicle controls carried out in adjacent arterial segments from the
ame patient. In separate, time-dependant studies (see Fig. 1D),
 single concentration (10 mol/L) of AEA was added to pre-
ontracted arteries of larger diameter (1–2 mm)  and changes in
ension were recorded for 2 h.
.2. Mechanisms of action
In all interventions to assess mechanisms of action, AEA control
esponses were carried out simultaneously in adjacent arter-
es from the same patient. Cannabinoid receptor involvement
as assessed with a CB1 antagonist AM251 (100 nmol/L, 10 min
efore contraction of the artery), CB2 receptor antagonist AM630
100 nmol/L, 10 min  before contraction of the artery) and CBe antag-
nist O-1918 (10 mol/L, 10 min  before contraction of the artery).
esensitisation of TRP receptors was achieved via incubation (1 h)
ith capsaicin (10 mol/L). The potential involvement of PPAR
as investigated using the antagonist GW9662 (1 mol/L, 10 min
efore contraction of the artery). AEA responses were also exam-
ned after endothelium denudation (with a human hair), incubation
ith the fatty acid amide hydrolase (FAAH) inhibitor URB597
1 mol/L, 30 min  before contraction of the artery and present
hroughout), the COX inhibitor indomethacin (10 mol/L, 30 min
efore contraction of the artery and present throughout) or the
OS inhibitor, N-Nitro-l-arginine methyl ester hydrochloride (L
AME, 300 mol/L, present throughout). None of the interventions
ested signiﬁcantly affected the levels of tone prior to addition of
EA.uares show responses for cannabinoid ligands. Data points represent means with
vehicle) artery segments from the same patient were made using 2 way repeated
< 0.01, **** P < 0.0001.
2.3. Cell culture
Human aortic endothelial cells (HAECs, PromoCell, Germany,
passage 4) were grown in PromoCell Endothelial Cell Growth
medium to conﬂuence on 6 well plates and treated for 10 min  with
10 mol/L AEA or the synthetic CB1 agonist CP55950 (1 mol/L),
after which time the medium was  removed and the cells collected
in cell lysis buffer (RIPA buffer, SigmaAldrich) with phosphatase
and protease inhibitors (Roche). The protein concentration of the
cell lysate was  measured using a BCA assay (Sigma Aldrich). The
levels of phosphorylated ERK/MAP kinase 1/2 (Thr185/Tyr187),
Akt (Ser473), STAT3 (Ser727), JNK (Thr183/Tyr185), p70 S6 kinase
(Thr412), NFB (Ser536), STAT5A/B (Tyr694/699), CREB (Ser133),
and p38 (Thr180/Tyr182) were measured in cell lysates using the
Luminex® xMAP® technology using a commercially available panel
for screening signalling pathways (MilliplexTM, 48-680MAG, Merck
Millipore), and normalised to total protein content.
2.4. RT-PCR
The presence of predicted sites of action was investigated at the
mRNA level using reverse transcription followed by polymerase
chain reaction (RT-PCR) as previously published [20,21]. Human
astrocytes (HAs) were used as a positive control known to express
all the target sites of action of interest [21]. Total RNA was extracted
from HAs and HAECs using Allprep DNA/RNA kit with on column
DNaseI treatment (Qiagen, Germany). Reverse transcription with
(+) and without reverse transcriptase (−) was performed in 20 l
ﬁnal volume using 2 g of total RNA and random primers with the
High Capacity cDNA Reverse Transcription Kit (Life Technologies,
UK). PCR reactions were carried out in a ﬁnal volume of 25 l with
Zymotaq (ZymoResearch, USA) using 2 l of reverse transcription
product as the template. After 5 min  at 95 ◦C, PCRs were performed
for 40 cycles except those for CGRPR and CB2R that were carried out
for 60 cycles. The cycles included 30 s at 95 ◦C, 30 s at the annealing
temperature that was  optimal for each primer pair (56 ◦C for CB1R
and CB2R; 60 ◦C for HPRT; 58 ◦C for TRPV1; 61 ◦C for CGRPR) and
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a
s
2
u
2
r
t
f
G
v
m
t
(
a
R
b
p
w
S
3
3
h
(
s
F
b
i
t
C
−
(
v
a
l
n
a
3
b
C
c
w
R
A
v
3
n
i
C
a
t
C
f
Fig. 2. Anandamide-induced vasorelaxation is not altered by inhibition of its
metabolism, but it is endothelium-dependent. Anandamide concentration-response
curves in the presence of the fatty acid amide hydrolase inhibitor URB597 (A, n = 5
patients), after removal of the endothelium (B, n = 5 patients), in the presence of
the  non-selective cyclooxygenase inhibitor indomethacin (C, n = 7 patients), and
in  the presence of the nitric oxide synthase inhibitor L-NAME (D, n = 6 patients).
Open squares show data points for anandamide control and closed squares show
responses for anandamide with intervention. Data points represent means withC.P. Stanley et al. / Pharmacolo
 ﬁnal extension step of 30 s at 72 ◦C. Ampliﬁcation products were
eparated by gel electrophoresis through ethidium bromide stained
% agarose (CB1R, CB2R, TRPV1, CGRPR and HPRT) and visualised
sing a Biorad Chemidoc.
.5. Statistical analysis
Graphs represent mean percentage relaxations, with error bars
epresenting the standard error of the mean (SEM), and n equalling
he number of patients. Rmax and EC50 values were obtained
rom sigmoidal concentration-responses curves (Prism Version 5;
raphPad Software, California, USA). Comparisons between inter-
ention and control artery segments from the same patient were
ade using 2 way repeated measures ANOVA with Sidak’s mul-
iple comparison at each concentration. The area under the curve
AUC) of concentration-response curves was calculated using Prism
nd this data was used to identify any statistical outliers using the
out method. One patient was excluded from the ﬁnal analysis
ased on this outlier analysis. The potential relationship between
atient characteristics and the anandamide AUC responses (which
ere normally distributed) were analysed by Pearsons correlation.
igniﬁcance was determined at P < 0.05.
. Results
.1. AEA causes acute and time-dependent vasorelaxation of
uman mesenteric arteries
AEA caused acute vasorelaxation of human mesenteric arteries
700 ± 49 m diameter) with an Rmax 29 ± 3% and EC50 −5.7 ± 0.3
igniﬁcantly different to vehicle between 3 and 100 mol/L (n = 12,
ig. 1A & B). AEA caused a modest (but not signiﬁcant) reduction in
aseline tone when added to uncontracted arteries (Fig. 1C). As AEA
s a partial agonist of both CB1 and CB2 receptors, full agonists of
hese receptors, CP55,940 (CB1) and HU308 (CB2), were also tested.
P55,940 caused vasorelaxation with an Rmax 60 ± 3.6% and EC50
5.2 ± 0.1 signiﬁcantly different to vehicle control from 1 mol/L
n = 12, Fig. 1E). HU308 had no effect on vascular tone compared to
ehicle (Fig. 1F).
When a single concentration of AEA (10 mol/L) was  added in
rteries of a larger diameter (1–2 mm),  AEA caused an initial vasore-
axation that was signiﬁcantly different to vehicle control (P < 0.05),
on-recoverable and increased over time (see Fig. 1D). This was not
ffected by the PPAR antagonist GW9962 (Fig. 1D).
.2. AEA-induced vasorelaxation is not limited by its metabolism,
ut is endothelium-dependent
Incubation with the FAAH inhibitor URB597 (Fig. 2A) or the
OX inhibitor indomethacin or (Fig. 2C) did not modify AEA
oncentration-response curves, therefore, no further experiments
ere performed to test prostanoids (or other metabolite) pathways.
emoval of the endothelium inhibited the vasorelaxant effects of
EA (P < 0.05, Fig. 2B). Incubation with L-NAME also reduced the
asorelaxant effects of AEA (P < 0.01–0.05, Fig. 2D).
.3. AEA-induced vasorelaxation is dependent on CB1 and CBe but
ot CB2 or TRPV channels
Antagonism of the CB1 receptor using AM251 (100 nmol/L)
nhibited AEA responses from 3 mol/L (Fig. 3A). Antagonism of the
B2 receptor (AM630, 100 nmol/L) did not alter AEA-induced relax-
tion (Fig. 3B), consistent with the lack of a vasorelaxant response
o the CB2 agonist HU308 (Fig. 1F). Antagonism of the putative
Be receptor using O-1918 (1 mol/L), inhibited AEA responses
rom 3 mol/L (Fig. 3C). Desensitisation of TRPV receptors usingerror bars showing SEM. Comparisons between intervention and control (AEA alone)
artery segments from the same patient were made using 2 way  repeated measures
ANOVA with Sidak’s multiple comparison at each concentration. * P < 0.05, ** P < 0.01.
capsaicin (10 mol/L) did not affect AEA-induced vasorelaxation
(Fig. 3D). To conﬁrm the presence of these target sites at the RNA
level in the endothelium (see Fig. 2B), RT-PCR was carried out
in human aortic endothelial cells (HAECs) where the expression
of presence of CB1 but not CB2 receptors was shown using rele-
vant primers (Fig. 3E). As a positive control, the expression of CB2
was observed in human astrocytes [21] (Fig. 3E). Although AEA
responses were not affected by capsaicin pre-treatment (Fig. 3D) as
in animal studies [22], TRPV1 and the CGRP receptor mRNA were
present in HAECs.
3.3. Intracellular signalling responses to AEA and CP55940 in
HAEC cells
In HAECs, AEA (10 mol/L) and the CB1 agonist CP55,940
(1 mol/L) signiﬁcantly increased the levels of phosphorylated JNK,
NFB, p70s6K, STAT3, STAT5, ERK 1/2 and Akt to similar levels
(Fig. 4B– I). AEA, but not CP55,940, also increased phosphorylation
of p38 (Fig. 4D). There was  no signiﬁcant difference between AEA
and CP55,940 in any of the signalling proteins tested.
3.4. The effects of patient characteristics on AEA responses
Considerable differences were observed in the AEA vasorelaxant
responses across patients. Therefore, post-hoc analysis of patient
responses was  carried out to establish any potential relationships
between AEA-induced vasorelaxant and patient characteristics.
Vasorelaxant responses to AEA did not correlate with patient
age (r = 0.1025, Fig. 5A), gender (Fig. 5E) or mean arterial blood
pressure (r = −0.0292, Fig. 5D; SBP and DBP were also not corre-
lated with AEA responses, data not shown). A signiﬁcant negative
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Fig. 3. Anandamide-induced vasorelaxation is reduced by antagonism of the CB1 and CBe receptors. Anandamide (AEA) concentration-response curves in the presence of
the  CB1 inhibitor AM251 (A, n = 6 patients), the CB2 inhibitor AM630 (B, n = 4 patients), the CBe inhibitor O-1918 (C, n = 5 patients), and after desensitisation of the TRPV
receptors using capsaicin (D, n = 4 patients). Open squares show data points for AEA control responses and closed squares show responses for AEA with intervention. Data
points  represent means with error bars showing SEM. Comparisons between intervention and control (AEA alone) artery segments from the same patient were made using
2  way  repeated measures ANOVA with Sidak’s multiple comparison at each concentration. ** P < 0.01, *** P < 0.001, **** P < 0.0001. E. RT-PCR showing the presence of CB1,
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orrelation was observed between the response to AEA (total
esponse to AEA calculated as the area under the curve (AUC)) to
MI  (r = −0.5003, P < 0.01, Fig. 5B) and body weight (r = −0.6096,
 < 0.0001, Fig. 5C). AEA responses were not altered in patients
ith diabetes (Fig. 5F), cancer (Fig. 5G), or hypercholesterolaemia
Fig. 5H) or in patients taking ACE inhibitors, hypoglycaemic agents,
SAIDS, beta-blockers (data not shown) or statins (Fig. 5J). How-
ver, the vasorelaxant response to AEA was signiﬁcantly blunted in
hose taking paracetamol/co-codamol (P < 0.01, Fig. 5I).
. Discussion
The aim of this study was to explore the effects of AEA in human
esenteric arteries, to establish the target sites at which AEA acts,
nd test if the effects of AEA were affected by patient characteris-
ics. AEA caused moderate endothelium-dependent vasorelaxation
f human mesenteric arteries, which was inhibited by antagonism
f CB1 and an uncharacterised endothelial cannabinoid receptor
CBe). CB2 activation did not cause vasorelaxation of human mesen-
eric arteries. The mechanisms underpinning vasorelaxation to AEA
how both similarities (roles for the endothelium and CB1) and
ifferences (no roles for metabolism or TRP channel activation) to
hat observed in animal studies. AEA-induced vasorelaxation was
ot signiﬁcantly altered by gender, age or patient medical condi-
ions, but was reduced in overweight patients, and in those taking
aracetamol containing medications.
Previous studies in rat mesenteric arteries have shown that
ow micromolar concentrations of AEA cause maximal vasore-
axation [5,6]. In human pulmonary arteries, AEA also caused
aximal vasorelaxation [23]. However, in the present study, bothhe potency and efﬁcacy of AEA were lower. As metabolism of AEA
as been shown to limit its vasorelaxant effects in the rat mesen-
ery [6], we hypothesised that the lower efﬁcacy of AEA might be
ecause of its degradation in human mesenteric arteries. How-xanthine-guanine phosphoribosyltransferase (HPRT) was used as a house-keeping
hout reverse transcriptase. Human astrocytes (HA) are shown as a positive control
ever, we  found that inhibition of FAAH or COX had no effect on
the vasorelaxant response to AEA. This is interesting because we
recently found that metabolism of 2-AG to vasoactive substances
was the main mechanism of action underpinning vasorelaxation
to 2-AG in human mesenteric arteries [11]. This could be because
2-AG is less metabolically stable than AEA, and may  explain the
reduced efﬁcacy of AEA in the present study compared to 2-AG
[11]. Another possible explanation for the reduced efﬁcacy of AEA
is that our patient population were undergoing surgery, were older
and had a variety of comorbidities potentially associated with vas-
cular dysfunction. Indeed our post hoc analysis showed that AEA
responses were blunted in overweight patients and those taking
paracetamol. However, when we looked at the responses curves to
AEA in the patients with a BMI  less than 25 and not taking parac-
etamol, the maximal vasorelaxant response to AEA was still only
44% (n = 6), suggesting a lower maximal response to AEA in human
mesenteric arteries is likely.
In line with many animal studies [2], we found that the vasore-
laxant response to AEA was  inhibited by CB1 receptor antagonism.
We also found that a synthetic CB1 agonist (CP55,940) caused
vasorelaxant in human mesenteric arteries (albeit a greater Rmax,
probably reﬂecting the greater potency and efﬁcacy at CB1), and
conﬁrmed the presence of CB1 mRNA in human aortic endothelial
cells (which we have also demonstrated in human brain microvas-
cular endothelial cells [21]). In these cells, AEA shared a similar
signalling proﬁle as the archetypical CB1 ligand CP55,940, and
caused phosphorylation of the intracellular proteins p38 MAPK,
ERK1/2 MAPK and Akt, all of which have previously been asso-
ciated with AEA signalling [39,40] and activation of eNOS [41].
Taken together with the L-NAME data, this suggests that part of the
vasorelaxation seen to AEA in human arteries is through cannabi-
noid receptor signalling to MAPKs and Akt activating eNOS. Other
human studies, albeit in pulmonary arteries, have not found a role
for the CB1 receptor in cannabinoid-induced vasorelaxation [10].
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Fig. 4. Anandamide and CP55940 show similar proﬁles of intracellular signalling proteins in human aortic endothelial cells. Levels of phosphorylated CREB (A), JNK (B), NFB
(C),  p38 (D), ERK/MAP kinase 1/2 (E), Akt (F), p70s6K (G), STAT3 (H) and STAT5 (I) were measured in endothelial cell lysates after 10 min  incubation with anandamide (AEA;
10  M) or CP55940 (1 M)  using the Luminex® xMAP® technology and normalised to total protein content. Data are presented as mean with SEM and were analysed by
one-way  ANOVA with Dunnett’s comparison against the vehicle control response (n = 6). ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Fig. 5. Post-hoc analysis of anandamide responses. Correlation between the total response to AEA (area under the curve, AUC) and age (A), BMI (B), body weight (C) and
mean  arterial pressure (D). AUC responses to AEA in males and females (E), patients with and without type 2 diabetes (F), cancer (G), hypercholesterolaemia (H) or those
taking  paracetamol (I) or statins (J). A–D were analysed by Pearsons correlation and E–J were analysed by unpaired t-test. **P < 0.01, ***P < 0.001.
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his probably reﬂects regional difference in vascular CB1 expres-
ion.
In contrast, the CB2 ligand HU-308 had no effect on vascular
one, and the vasorelaxant response to AEA was not affected by
B2 receptor antagonism. This is in agreement with a lack of a role
or CB2 in cannabinoid-mediated vasorelaxation in animal studies
2]. We  also found that CB2 was not expressed in human aortic
ndothelial cells. It is likely, however, that CB2 is upregulated in
he vasculature in pathologies such as atherosclerosis, where an
nti-inﬂammatory role for CB2 activation has been identiﬁed [25],
nd we recently showed that high glucose or high insulin treatment
ncreases the mRNA of CB2 in endothelial cells [20].
The existence of a novel cannabinoid receptor located exclu-
ively on the endothelium was ﬁrst suggested in 1999 [26]. This
eceptor has been implicated in animal studies to be involved in
ediating vasorelaxation to a range of cannabinoids in a variety of
ascular beds, and is antagonised by an analogue of cannabidiol,
1918 [5,26–28]. In agreement with these studies, we  found that
he effects of AEA in human mesenteric arteries were reduced by
emoval of the endothelium and in the presence of O-1918, further
uggesting the existence of the proposed CBe receptor in humans
10,23,29]. The exact identity of this receptor is still unknown but a
romising candidate is the orphan receptor GPR18. It follows a sim-
lar ligand binding proﬁle to that of the CBe receptor [30], and has
een shown to be present in the endothelium of rat retinal arteries
31].
The response of AEA was unaltered by TRPV channel desensiti-
ation by capsaicin in the present study. This is in contrast to animal
tudies, which have shown a signiﬁcant role of TRPV activation with
ubsequent CGRP release [2]. We  have recently shown a role for
he TRPV1 channel in mediating the vasorelaxant response to CBD
32] and capsaicin (unpublished data) in the same human mesen-
eric arteries, and have demonstrated the presence of both TRPV1
nd the CGRP receptor in human aortic endothelial cells. Thus, the
ssue is unlikely to be that TRPV1 is not expressed in these arter-
es. AEA requires facilitated transport across the cell membrane to
ctivate TRPV1 [33], therefore a possible explanation is that insuf-
cient levels of AEA are reaching the intracellular binding site of
RPV1.
In larger conduit arteries such as the aorta and superior mesen-
eric artery, we have shown that cannabinoids, including AEA, cause
 time-dependent vasorelaxation mediated by PPAR [34,35]. To
est whether a similar response to AEA was observed in human
esenteric arteries, we selected arteries of the largest diameter
vailable to us in the mesenteric samples (1–2 mm).  Application
f a single concentration AEA caused a non-recoverable vasorelax-
tion signiﬁcantly different to vehicle over 2 h. However, unlike in
he rat aorta, this response was not affected by a PPAR antago-
ist. This is probably due to the size of the arteries in the present
tudy, as we previously showed that the PPAR-mediated time-
ependent response to AEA was only observed in larger conduit
rteries such as the aorta and superior mesenteric artery, and not
n smaller resistance vessels of the mesenteric bed [36].
To identify any trends in the effects of patient characteristics,
o-morbidities or medication on AEA responses, we carried out
ost hoc analysis which revealed two inﬂuences on AEA responses;
MI/body mass and paracetamol. A similar effect of obesity on AEA
esponse has been identiﬁed in Zucker rats [19], where the reduced
asorelaxation to AEA was  due to decreased CB1 and TRPV1 con-
ribution, increased AEA degradation, and a decreased ability of
EA to stimulate eNOS. There is also evidence in the literature
f interactions between the endocannabinoid system and parac-
tamol. AM404 is a metabolite of paracetamol that inhibits AEA
ransport and FAAH activity which would prevent AEA degradation,
37] and AM404 also activates TRPV1[38]. Thus taking paracetamolesearch 113 (2016) 356–363
may  interfere with the vascular actions of AEA, which warrants
further investigation.
In conclusion, AEA causes endothelium-dependent, NO-
dependent vasorelaxation in human mesenteric arteries that is less
efﬁcacious than in animal models. Unlike in rat mesenteric arter-
ies, AEA-induced vasorelaxation in human mesenteric arties is not
limited by its metabolism or inhibited by TRPV channel desensiti-
sation. However, similar to that observed in rat mesenteric arteries,
AEA-mediated vasorelaxation is dependent on CB1 and CBe recep-
tor activation. Post hoc analysis of the data set suggest that obesity
and taking paracetamol reduce the vasorelaxant response to AEA.
These ﬁndings demonstrate a role for AEA in modulating vascular
tone in humans mediated by CB1 and the endothelium.
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